Danvatirsen

DRUG6 trials

Conditions

AML/MDSAcute Myeloid LeukemiaAdvanced Colorectal CarcinomaAdvanced Lung Non-Small Cell CarcinomaEarly-stageHNSCCLung Non-Small Cell CarcinomaMetastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruitingNCT03819465

AstraZenecaMetastatic Non-Small Cell Lung Cancer (NSCLC)

Start: 2018-12-27End: 2026-03-26Updated: 2026-02-11

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

RecruitingNCT05986240

Montefiore Medical CenterAcute Myeloid Leukemia, AML/MDS, Myelodysplastic Syndromes

Start: 2024-05-08End: 2030-03-31Target: 38Updated: 2025-11-10

Phase 2

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Active, not recruitingNCT02983578

M.D. Anderson Cancer CenterAdvanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma +22

Start: 2017-03-02End: 2025-08-30Updated: 2025-05-06

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Active, not recruitingNCT03334617

AstraZenecaNon-Small Cell Lung Cancer

Start: 2017-12-18End: 2026-09-11Updated: 2025-10-27

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

CompletedNCT03794544

MedImmune LLCEarly-stage, NSCLC, Resectable

Start: 2019-03-08End: 2021-01-13Updated: 2022-02-24

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

TerminatedNCT05814666

Flamingo Therapeutics NVHNSCC

Start: 2023-05-30End: 2025-08-14Updated: 2026-01-30

2025-11-07

Abstract 2244: ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies

Cancer Research2025-04-21

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Blood2024-11-051 citations

STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells

Blood2024-11-05

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study

Journal for ImmunoTherapy of Cancer2024-09-0110 citations

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Future Oncology2024-07-1830 citations

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

BMJ Oncology2024-07-015 citations

PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).

Journal of Clinical Oncology2024-06-011 citations

Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?

The Oncologist2024-04-011 citations

Abstract 2023: Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST

Cancer Research2024-03-22

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Nature Medicine2024-02-13100 citations

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2024-02-0141 citations

695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

Regular and Young Investigator Award Abstracts2023-10-315 citations

Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)

Cancer Research2023-04-144 citations

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Cancer Immunology Immunotherapy2023-04-0589 citations

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

OncoImmunology2022-06-1846 citations

Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

Cancer Research2022-06-1522 citations

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Cancer Research2022-06-153 citations

Abstract LB016: Deep learning identifies pathobiological features within H&E images associated with genomic alterations and progression on anti-PD(L)1 in HUDSON, an AstraZeneca-sponsored Phase II clinical trial

Cancer Research2021-07-01

Somatic <i>STK11/LKB1</i> mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.

Journal of Clinical Oncology2018-05-2024 citations

1 more papers not shown

Danvatirsen

Sponsors

Conditions

Phase 1

Phase 2

Related Papers